Biofilm-Associated Urinary Tract Infections and Probiotics as Anti-Biofilm Agents
BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences · 05.06.2026
DOI: 10.70099/bj/2026.03.02.11 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences, online erschienen am 05.06.2026. Verfasst von Devi Chhatrodiya und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Urinary Tract Infections (UTIs) represent one of the most common bacterial infections worldwide, affecting annually about 150 million people globally Recurrent and persistent infections are generally caused by the formation of biofilms that develop when uropathogens colonize a surface and form multi-cellular communities encased within an extracellular polymeric substance (EPS) matrix. Biofilm associated bacteria are poorly recognized by the host immune response and are highly resistant to antibiotics due to poor antibiotic diffusion into biofilms, metabolic heterogeneity within biofilms, quorum sensing and persister cells leading to the development of multi-drug resistance and leading to treatment failure. Probiotics, particularly Lactobacillus species being a commonly used strain, have emerged as a possible adjunctive treatment for the prevention and management of biofilm associated UTIs. The probiotics can exert multiple anti-biofilm effects such as competing with pathogens in adhesion sites, production of bacteriocins and organic acids, bio-surfactants which interferes with adhesion and biofilm formation, altering pH, interfering with quorum sensing (QS) signals and biofilm destruction. The beneficial effects of probiotics are also attributed to their biofilm inhibitory effects along with their ability to enhance mucosal barrier function and modulate the immune system. Targeted probiotics can help prevent recurrence, restore microbial balance, and boost antibiotic performance while reducing drug resistance. However, standardized formulas and rigorous clinical trials are still needed to confirm their reliability.
Zitieren
APA
Chhatrodiya, D., Sumra, N., Sikotariya, B., & Aparnathi, S. (2026). Biofilm-Associated Urinary Tract Infections and Probiotics as Anti-Biofilm Agents. BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences. https://doi.org/10.70099/bj/2026.03.02.11
Vancouver
Chhatrodiya D, Sumra N, Sikotariya B, Aparnathi S. Biofilm-Associated Urinary Tract Infections and Probiotics as Anti-Biofilm Agents. BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences. 2026. doi:10.70099/bj/2026.03.02.11
BibTeX
@article{Chhatrodiya2026,
author = {Chhatrodiya, Devi and Sumra, Nameera and Sikotariya, Bhumika and Aparnathi, Shubhamgiri},
title = {Biofilm-Associated Urinary Tract Infections and Probiotics as Anti-Biofilm Agents},
journal = {BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences},
year = {2026},
doi = {10.70099/bj/2026.03.02.11}
}
EUVIMED